Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Anticancer Res ; 42(6): 2847-2857, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35641258

RESUMEN

BACKGROUND/AIM: The objective of this study was to prepare doxorubicin encapsulated in micelles (DOX-micelles) using poly(hexadecanyloxyethylene glycol-lactate phosphate), which we recently synthesized, and to evaluate the anticancer effect of DOX-micelles in vitro and in vivo. MATERIALS AND METHODS: To evaluate the anticancer effect of DOX-micelles in vitro, three-dimensional spheroids composed of B16 mouse melanoma cells and fibroblasts were prepared by changing the ratio of cancer cells to fibroblasts. In addition, for efficient doxorubicin treatment of the cells present in the center of the spheroids, tranilast, an anti-fibrotic drug was added to the spheroids before treatment with DOX-micelles, then the amount of doxorubicin and cell viability of spheroids were evaluated. Moreover, to assess the effects of the combination of DOX-micelles with tranilast in vivo, relative tumor volume was investigated in a mouse model of melanoma. RESULTS: The mean diameter and doxorubicin content of DOX-micelles were 93.3 nm and 3.5%, respectively. When the ratio of cancer cells to fibroblasts was 20:80, spheroids with spherical and rigid shapes were obtained. In addition, the amount of doxorubicin in the spheroids was increased by tranilast treatment, and an efficient anticancer effect was also observed. The anticancer effect of the combination of tranilast and DOX-micelles was confirmed in vivo. CONCLUSION: Micelles encapsulating doxorubicin are promising for cancer therapy, and their anticancer effect is improved by tranilast pretreatment in 3D spheroids in vivo.


Asunto(s)
Melanoma , Micelas , Animales , Antibióticos Antineoplásicos/farmacología , Doxorrubicina , Portadores de Fármacos , Humanos , Melanoma/tratamiento farmacológico , Ratones , ortoaminobenzoatos
2.
Anticancer Res ; 42(4): 1801-1811, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-35346998

RESUMEN

BACKGROUND/AIM: Serious side effects are associated with the use of doxorubicin. Nanoparticles as carriers for anticancer drugs are useful for reducing side effects and improving therapeutic effects. In this study, a polymer for preparing doxorubicin-containing nanoparticles was developed. Using a novel strategy, a biodegradable poly(oxyethylene glycol lactate H-phosphonate) based on dimethyl H-phosphonate and poly(ethylene glycol)-lactate (PEG-lactate) was synthesized. MATERIALS AND METHODS: Poly(hexadecanyloxyethylene - lactate phosphate) was obtained via chlorination of poly(oxyethylene glycol - lactate H-phosphonate) with trichloroisocyanuric acid and the addition of 1-hexadecanol. The polymer was characterized by 1H NMR and 31P NMR. RESULTS: The results of 1H NMR and 31P NMR showed that the polymer was successfully synthesized, and the yield was 46.9%. CONCLUSION: Poly(hexadecanyloxyethylene - lactate phosphate) has potential as a drug carrier.


Asunto(s)
Ácido Láctico , Fosfatos , Doxorrubicina/química , Portadores de Fármacos/química , Humanos , Poliésteres/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...